September 09, 2020

Chinese Biotech Sector is Blowing Hot as M&A and IPO Deals Surge Amid Covid-19 Pandemic

Toto Ku, Datasite Senior Sales Director, provides comments on the outlook for the Chinese biotech sector, including the surge in M&A and IPO deals amid the COVID-19 pandemic. The South Morning China Post article highlights findings from a recent webinar discussion on Deal Drivers in the Healthcare and Life Sciences: Mainland China.

Contacts

Media Relations
Marta Carraro

Vice President, Communications

212.367.6162

marta.carraro@datasite.com

Investor Relations
Jennifer Percy

651.632.4009

jennifer.percy@datasite.com

You may also like:

Mergers, Acquisitions and Exit Strategies

Comments from EMEA CRO Merlin Piscitelli on the importance of investors, sponsors, and target companies being aligned and deal ready to ensure a successful SPAC outcome, were published in The Times Raconteur Special Report, along with infographics based on data from our Deal Drivers: EMEA Q1 2021.

How Would a Global Corporation Tax Affect M&A Deals Involving U.K. Companies?

EMEA CRO Merlin Piscitelli shares his insights in Bloomberg Tax on how a universal corporation tax rate might potentially impact cross-border M&A activities, especially ones that include UK companies.

The Tech Sector Is Surging as Digital Transformation Continues to Drive M&A

CEO Rusty Wiley discusses some of the factors driving the M&A surge, and how dealmakers are leveraging technology to manage the increased volumes in this video interview with Nasdaq Trade Talks.